AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Why Did CARISMA Therapeutics Plunge 13.1%?
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jun 12, 2025 4:56 am ET1min read
On June 12, 2025,
experienced a significant drop of 13.1% in pre-market trading, reflecting a notable shift in investor sentiment.In recent weeks, CARISMA Therapeutics has seen dramatic fluctuations in its stock price. On June 10, the company's stock surged by 74.89% in pre-market trading, indicating a period of intense market interest. However, this rally was followed by a substantial correction, with the stock experiencing a -45.66% loss during regular trading hours on the same day. This volatility highlights the speculative nature of the market's response to the company's recent developments.
Additionally, the company faced challenges such as declining sales and a trending fatal crash report, which contributed to a 17% drop in its stock price over a 48-hour period. These factors, combined with broader market dynamics, have led to a period of uncertainty for CARISMA Therapeutics, as investors grapple with the company's future prospects.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Metallus shares plunge 6.73% as investor concerns over earnings volatility and sector risks grow
Dec.22 2025
Annexon (ANNX) Surges 7.26% in Pre-Market Trading After S&P Biotechnology Index Inclusion
Dec.22 2025
Aeva Technologies Inc. surges 7.69% on strategic partnership with major automaker
Dec.22 2025
Oracle shares surge 6.63% on OpenAI rebuttal and healthcare contracts
Dec.22 2025
Broadcom Inc. (NASDAQ:AVGO) surges 3.18% on analyst upgrades amid AI growth optimism
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet